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Abstract
In patients with chronic lymphocytic leukemia (CLL), a single neoplastic antigen-specific B cell 
accumulates and overgrows other B cells, leading to immune deficiency. CLL is often treated with 
drugs that ablate all B cells, leading to further weakening of humoral immunity, and a more 
focused therapeutic strategy capable of targeting only the pathogenic B cells would represent a 
significant advance. One approach to this would be to develop synthetic surrogates of the CLL 
antigens allowing differentiation of the CLL cells and healthy B cells in a patient. Here, we 
describe discovery of non-peptidic molecules capable of targeting antigen-specific B cell receptors 
with good affinity and selectivity using a combinatorial library screen. We demonstrate that our hit 
compounds act as synthetic antigen surrogates and recognize CLL cells and not healthy B cells. 
Additionally, we argue that the technology we developed can be used for discovery of other 
classes of antigen surrogates.
Keywords
Chronic Lymphocytic Leukemia; Combinatorial Chemistry; B Cell Receptor; Antigen Surrogate; 
Antibody
Chronic lymphocytic leukemia (CLL) is a cancer of B lymphocytes that occurs via the 
relentless accumulation of a single antigen-specific B cell clone (Chiorazzi et al., 2005). The 
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nature of the antigens that drive these events in CLL patients are generally not known 
(Catera et al., 2008; Chu et al., 2010). Like many diseases of the immune system, CLL is 
often treated with immunosuppressive compounds (Porter et al., 2011). For example, 
monoclonal antibodies (mAbs) such as rituximab that eliminate all CD20+ B cells are 
employed commonly in combination with systemic chemotherapy (Jaglowski et al., 2010). 
There is also great interest in targeting molecules involved in, or associated with, B cell 
activation, such as Bruton's tyrosine kinase (Byrd et al., 2013). However, while these B cell-
targeted drugs are a great improvement over standard cytotoxic chemotherapy for CLL and 
other B cell malignancies, they fail to discriminate between healthy and pathogenic B cells 
and thus leave the patient without a functional humoral immune system. Therapeutics 
selective for the pathogenic B cells would be of considerable interest. An intriguing target 
for such a strategy would be the antigen-specific surface membrane immunoglobulin (smIg) 
component of the B Cell Receptor (BCR) of the pathogenic lymphocytes.
Indeed, Levy and co-workers have shown that vaccination of CLL patients with their own Ig 
can induce useful anti-idiotype antibodies and T cells that selectively target the pathogenic B 
cell clones and recruit effector functions to them, resulting in their elimination (Meeker et 
al., 1985). This strategy that has been applied to other B-cell malignancies as well 
(Timmerman et al., 2009). Excellent clinical efficacy has been observed in several cases, 
providing compelling evidence for the feasibility of a strategy that selectively targets only 
the pathogenic cells. However, there has been little progress on the development of drug 
candidates that are selective for pathogenic B cells. In this vein, one would require a highly 
selective ligand capable of binding to the antigen-binding site of the leukemic Ig that could 
be tailored to carry a toxic cargo. While BCR-targeting antibody-drug conjugates (ADCs) 
could be imagined as potential therapeutics, similar to the CD30-targeting ADC that is 
approved for Hodgkin lymphoma (Bander et al., 2012), their production is technically 
challenging (Adem et al., 2014) and antibodies are able to carry only a small amount of drug 
payload, necessitating the use of only a few extremely toxic compounds (Anderl et al., 
2013). Easily manipulable synthetic ligands for leukemic Igs would have several advantages 
in this regard. To the best of our knowledge however, the only report of synthetic ligands 
that recognize an antigen-specific CLL Ig are 12-residue peptides isolated via phage display 
(Seiler et al., 2009). Simple linear peptides are poor candidates for this application since 
they have limited stability in serum. More drug-like molecules with this type of binding 
selectivity are unknown.
Here we report a potentially general approach to screen synthetic one bead one compound 
(OBOC) libraries to identify leukemic Ig-binding “antigen surrogates”. In this study, a 
library of molecules called COPAs (chiral oligomers of pentenoic acids) (Aquino et al., 
2011) (Fig. 1) was mined for such ligands. These polyketide-inspired molecules are 
calculated to adopt discreet conformations determined by the absolute chirality in each 
monomeric unit (Aquino et al., 2011). Thus, oligomers of these units are predicted to be 
much “stiffer” than relatively “floppy” small peptides and peptoids and are expected to be a 
superior source of protein ligands. In line with this expectation, previous work (Aquino et 
al., 2011) has shown that libraries of COPAs are capable of providing ligands to protein 
targets for which no good binders could be mined from a comparable library of peptoids. 
Indeed, COPA ligands for antigen-specific CLL Igs are described in this study that bind 
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selectively with sub-micromolar affinities to a soluble, recombinant CLL patient-derived 
monoclonal Ig. When displayed on a multimeric scaffold, these ligands distinguish between 
cells that express different antigen-specific Igs. This work represents the critical first step in 
the development of non-peptidic, drug-like molecules capable of distinguishing pathogenic 
from healthy lymphocytes.
Results
A screen for synthetic “antigen surrogates”
We hypothesized that one could mine COPA libraries for high affinity and selectivity 
ligands that would recognize the antigen-binding site of CLL patient-derived smIgs by first 
denuding the library of ligands to conserved regions of IgGs and then screening the 
remainder of the library against one or a few antigen-specific targets. To test this idea, a 
library of COPAs with the general structure shown in Fig. 1 was constructed. The library, 
which has a theoretical diversity of 1.28 million compounds, was created using 2.5 g of 160 
µm TentaGel beads (≈ 1.3 million beads) using split and pool solid-phase synthesis (Aquino 
et al., 2011). The beads were suspended in buffer containing a high concentration of BSA, 
and then exposed to a mixture of human IgG antibodies obtained from individuals that did 
not suffer from CLL (Fig. 2). After washing, the beads were exposed to a red quantum dot-
conjugated anti-human IgG secondary antibody. The beads that bound significant levels of 
the human IgG antibodies, or bound directly to the secondary antibody preparation, acquired 
an intense red fluorescence. These beads were removed from the population manually using 
a pipette under a low power fluorescence microscope.
We assumed that the remainder of the beads should be largely devoid of ligands for 
conserved regions of human IgGs. Thus, these beads were incubated with three soluble 
recombinant CLL monoclonal Igs, expressed and purified from HEK 293 T cells (called 
CLL 068, 169 and 183, respectively (100 nM each)). Again, subsequent incubation with the 
fluorescently labeled secondary antibody was employed to “light up” the “hits”. A total of 
one hundred ten beads fluoresced bright red and were collected.
Since the re-synthesis and analysis of screening hits is the most time-consuming portion of 
this type of discovery experiment, we chose to repeat the experiment on these 110 putative 
hits. Therefore, antibodies were stripped from the beads using a denaturing buffer. After re-
equilibration, the beads were again exposed to control human IgG followed by the labeled 
secondary antibody. Beads that emitted any observable fluorescence were eliminated from 
the population. Those that did not were then exposed to each of the three CLL Igs, one at a 
time, followed by labeled secondary antibody. At each step the bright beads were harvested. 
This resulted in 18 hits against CLL 169 and 13 hits against CLL 183 mAb. None of the 
beads bound significant levels of CLL 068, indicating that there were no high affinity 
ligands for the antigen-binding site of this Ig in the COPA library employed.
The beads displaying putative CLL 169 and 183 ligands were placed in individual wells of a 
96-well plate and treated with CNBr to release the compounds into solution via cleavage of 
the methionine residue in the conserved linker (Fig. 1). The molecules were analyzed by a 
combination of MALDI TOF-TOF and ESI-ETD mass spectrometry (Sarkar et al., 2013). 
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From these data the structures of 14 of the CLL 169 hits and 9 of the CLL 183 hits could be 
elucidated unambiguously (Supp. Fig. S1). All of these compounds were re-synthesized and 
purified by HPLC. In each case, a C-terminal cysteine was included to facilitate site-specific 
labeling or surface immobilization of the COPA molecule (Supp Fig 2).
Biophysical analysis of COPA-antibody binding
To evaluate the affinities of these small molecules for their target, they were labeled with 
fluorescein and titrated with recombinant, soluble Ig. Binding was monitored by 
fluorescence polarization (FP) spectroscopy. Six of the 14 putative CLL 169 compounds 
showed clear binding in this experiment, with the best ligand, KMS5, exhibiting a KD of 
approximately 500 nM. (Supp. Fig. S3 a). Three out of 9 putative CLL 183 ligands were 
validated in this assay format exhibited KD values ranging from 0.6 μM to 3 μM (Supp. Fig. 
S3 b). Similar results were obtained when the compounds were biotinylated, immobilized on 
streptavidin-coated ELISA plates, and titrated with increasing amounts of soluble Ig (Fig. 3a 
and Supp. Fig. S3 c). The derived KD values were lower, presumably due to avidity effects.
The fact that the majority of the hits proved to be poor ligands in solution or on ELISA 
plates was not surprising. Work in our laboratory on small molecule-antibody interactions 
has shown that TentaGel beads are heterogeneous and that a small fraction of the bead 
population displays the compound at exceedingly high density, which probably allows very 
weak ligands that happen to be displayed at such densities on these rare beads to stably 
capture an antibody on the surface due to “kinetic trapping” effects (Doran et al., 2014).
Analysis of binding selectivity
To address the critical question of whether these compounds target the antigen-binding site 
of the CLL-specific smIg, the three that exhibited the highest affinity for CLL 169 (KMS5, 
KMS9 and KMS11) were immobilized on an ELISA plate and titrated with various soluble 
Igs (CLL 014, CLL 068 and CLL 183) as well as human serum IgG. Two of the compounds, 
KMS9 and KMS11, had modest selectivity for CLL 169 (Supp. Figs. S3 d and e), whereas 
binding of KMS5 to CLL 169 was highly selective (Fig. 3c). Moreover, a scrambled version 
of KMS5 bound to CLL 169 with a much lower affinity (Fig. 3). These data argue that 
KMS5 recognized the antigen-binding site of the CLL 169 Ig selectively.
To investigate this point further, a competition binding experiment was carried out against a 
12-residue peptide, called 169-8, shown previously to bind the antigen-binding site of CLL 
169 (Seiler et al., 2009). As shown in Fig. 4a, soluble COPA KMS5 competed binding of the 
CLL 169 IgG to immobilized KMS5, as expected. The same result was obtained when 
soluble peptide 169-8 was added to the CLL Ig, but a control soluble peptide had no effect. 
These data argue that KMS5 and peptide 169-8 compete for the same binding site on CLL 
169 monoclonal Ig.
The competition data in Fig. 4a also suggest that the affinity of the COPA and the peptide 
are similar. To validate this, ELISA experiments were conducted in which each compound, 
or a control COPA compound or peptide, was immobilized on the ELISA plate and titrated 
with CLL 169 IgG. As shown in Fig. 4b, this experimental format confirmed that the 
affinities of the peptide and COPA for CLL 169 are similar, with the peptide binding 
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approximately 2-fold more tightly (KD = 49 ± 11 nM for the peptide-IgG complex, KD = 90 
± 20 nM for the COPA-IgG complex). While the affinities are similar, the synthetic COPA 
compound is resistant to degradation by human serum proteases (Supp. Fig. 4) and thus 
would be preferable for selective drug delivery to CLL cells.
Selective recognition of cells expressing CLL-specific smIgs
With respect to the ultimate goal of delivering toxic cargo to CLL B cells, a critical issue is 
whether the COPA ligands can recognize the smIgs for which they were selected. Ig heavy 
chain secreted-expression plasmids (pIg-gamma) were re-engineered by introducing an IgG1 
transmembrane (TM) domain at the C-terminus (Supp. Figs. S5 a and b). HEK 293 T cells 
were transfected with these expression vectors and the expression levels of surface 
membrane IgGs was determined by staining the cells with anti-human Ig Fc specific 
antibody conjugated to allophycocyanin (anti-huIgFc-APC) and analyzing by flow 
cytometry (Fig. 5). As expected from a transient transfection, the population has a 
distribution of smIgG expression levels, reflected in the width of the peak in the flow 
cytometry plots.
Initial experiments, in which biotin-tagged KMS5 or biotin-tagged 169-8 peptide were 
incubated with cells displaying CLL 169 or other BCRs were unsuccessful. Only a modest 
amount of non-selective binding was observed (Supp. Figs. S5 c and d). We hypothesized 
that this is due to the modest affinity of these artificial CLL 169 ligands. Therefore, we 
turned to the multimerization of the peptide and COPA ligands in the hope that avidity 
effects would provide a more favorable result. Dextran was chosen as the backbone for these 
multimeric compounds given its excellent solubility and biocompatibility. An estimated 
average of 31 equivalents of KMS5 or peptide 169-8 was conjugated to biotinylated dextran 
using the chemistry depicted in Supp. Fig. S6. To investigate if these multivalent conjugates 
indeed increase the binding affinity for CLL 169 Ig, we carried out competition ELISAs 
using KMS5 and dextran conjugated KMS5 (Fig. 4a), and 169-8 peptide and dextran 
conjugated 169-8 peptide (Supp. Fig. 3f). Both of these experiments showed that 
multimerization increased the affinity of the compound for CLL 169 Ig by more than 10-
fold (Supp. Table S1). These polymers were then incubated with cells expressing the smIg 
form of CLL 169, one of three alternative CLL smIgs, or cells lacking any smIg. Binding 
was followed by staining with PE-conjugated streptavidin and flow cytometry.
As shown in Fig. 5, KMS5-Dextran showed significant binding to the cells expressing CLL 
169, exhibiting a plot similar to that observed when the CLL 169-displaying cells were 
incubated with the anti-huIg Fc-APC antibody. In contrast, only a small amount of binding 
of KMS5 to cells expressing any of the other CLL IgGs, or to the control cells, was 
observed. A similar result was obtained with the 169-8 peptide-dextran conjugate, again 
showing the similar behavior of the peptide and much smaller COPA ligand.
Selective binding of multivalent ligands with primary CLL cells from patients
Given these promising results using smIg-expressing cells, we evaluated the extent that 
KMS5 selectively recognized the patient-derived primary CLL B cells. Frozen peripheral 
blood mononuclear cells (PBMCs) containing the CLL 169 cells were thawed and allowed 
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to recover for 2 hours. To enrich for living B cells, the PBMCs were subjected to a Ficoll 
gradient and then a commercial kit (from Milteneyi Biotec) was employed to enrich B cells 
in the population by selectively depleting non-B cells. These cells were then incubated with 
biotin-tagged dextran-KMS5, the equivalent construct displaying peptide 169-8, or biotin-
dextran conjugates displaying a control COPA or peptide. After washing, the cells were then 
incubated with streptavidin-conjugated PE (to monitor binding of the dextran conjugates to 
the cells), anti-CD5-APC antibody and anti-CD19-FITC antibody (to identify the CD5+/
CD19+ CLL B cell population), and Po-Pro dye (to stain dead cells). Four-color flow 
cytometry was carried out to focus the analysis on binding of the dextran conjugates to 
living CLL B cells (Fig. 6a). As shown in Fig. 6b, the biotinylated dextran conjugates 
displaying the COPA KMS5 and the peptide 169-8 associated with the CLL 169 B cells 
(Q2, CD5+/CD19+), whereas biotinylated dextran conjugates displaying a control COPA or 
peptide did not. On the other hand, the biotinylated dextran conjugates did not exhibit any 
significant affinity for the small population of normal (non-CLL) B cells (Q3, CD5-/CD19+) 
from the same patient (Fig 6c). Furthermore, when the KMS5 and 169-8 conjugates were 
incubated with B cells isolated from a different CLL patient, no significant binding was 
observed (Fig. 6d). In this case, the level of signal in the PE channel observed when the 
KMS5 or 169-8 dextran-biotin conjugates were incubated with the cells was essentially 
identical to that observed when the cells were mixed with the control conjugates. 
Furthermore these, in turn, were similar to that observed when no dextran-biotin conjugate 
at all was used. The KMS5 and 169-8 conjugates also did not bind to the T-cell population 
(Q1, CD5+/CD19-) of CLL 169 PBMCs nor to the CLL cell line MEC1 (Supp. Fig. S7). The 
CLL 169 and control CLL B cells had similar levels of smIg, as determined by staining with 
anti-Human IgM (Fc5µ fragment specific) antibody as shown in Supp. Fig. 7d. Therefore, 
these data show that the KSM5-dextran conjugate (as well as the peptide 169-8-dextran 
conjugate) is a highly selective ligand for native B cells displaying the CLL 169 BCR. 
Notably, the binding is independent of the isotype of the BCR (IgG on HEK 293 T cells and 
IgM on CLL B cells), further corroborating selective targeting of the antigen-binding site.
Discussion
This study focused on determining the feasibility of screening combinatorial libraries of 
unnatural, non-peptidic compounds for ligands to antigen-specific B cell receptors. Such 
molecules could be used as “delivery agents” to bring toxic cargo or attract effector 
functions selectively to specific Ig-bearing cells, providing an attractive strategy to attack 
pathogenic B cells while sparing healthy B cells. High affinity ligands for a CLL Ig could 
also potentially be employed in a diagnostic mode, for example in a flow cytometry-based 
assay to monitor the return of the pathogenic B cell clone following initial chemotherapy. 
While BCR-binding (anti-idiotypic) antibodies and peptides have been described previously, 
to the best of our knowledge, there are no reports of synthetic, unnatural molecules capable 
of distinguishing B cells by their antigen specificity.
A library of COPA molecules (Fig. 1) was chosen as the starting point. These compounds 
are insensitive to serum peptidases that would rapidly degrade simple peptides (Supp. Fig. 
S4). The OBOC COPA library was first denuded of ligands for conserved regions of human 
IgG molecules by screening it against a mixture of antibodies from healthy controls and 
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removing binders with this step (Fig. 2). The remainder of the library was then screened 
against the recombinant, soluble version of CLL Igs. These hits were then stripped and re-
subjected to the screening conditions again to ensure that they were not artifacts. The 
structures of the compounds that bound one of the CLL Igs employed in this study were then 
deduced by mass spectrometry after release from the beads.
Several of the molecules identified in the screen proved to be good ligands for a particular 
CLL smIg, as evidenced by binding data from ELISA and fluorescence polarization 
experiments (Fig. 3 and Supp. Figs. S3). KMS5, the best ligand for the CLL 169 Ig was 
characterized in some detail. It bound to the antigen-binding site of the soluble version of 
this Ig with an affinity of approximately 500 nM in solution (Supp. Fig. 2a) and 90 nM when 
immobilized on an ELISA plate, the difference presumably reflecting avidity effects in the 
latter case. This affinity was similar to that displayed by a 12-residue peptide ligand for 
CLL169 isolated previously by phage display (Seiler et al., 2009) and the two compounds 
competed for the antibody, indicating recognition of the antigen-binding site.
Finally, while neither the biotin-labeled COPA KMS5 or peptide 169-8 could be seen to 
bind detectably to cells expressing the CLL 169-specific Ig, probably due to the kinetic 
instability of the complexes, selective binding was observed when either molecule was 
displayed on a biotinylated dextran polymer (Fig. 5), again likely due to avidity effects. We 
have found that ligands displayed on dextran can engage both arms of antibodies 
(Morimoto, et al., 2014) and there is the further opportunity for binding of a single dextran 
conjugate to multiple Igs on the cell surface. In experiments using HEK 293 T cells 
expressing membrane-anchored IgG, flow cytometry plots showed a clear shift in the 
fluorescence of the CLL 169-expressing cells, but not cells expressing CLL 014, CLL 068, 
CLL 183 or no BCR (Fig. 5). For the CLL 169-expressing cells, the gain in fluorescence 
was similar when the cells were incubated with the peptide-dextran complex, the COPA-
dextran complex or an anti-Fc antibody, indicating highly efficient binding. Similar results 
were observed using native B cells isolated form the CLL 169 patient and not from CLL 
cells from a different patient whose smIg was structurally distinct. Highly selective binding 
to the former was observed (Fig. 6).
In summary, we have developed a potentially general protocol for the isolation of non-
peptidic ligands for antigen-specific BCRs. The molecules that result from this screen have 
modest affinity, but high selectivity, for the antigen-binding site of the smIg of the primary 
leukemic cells of the original CLL patient. By oligomerizing these molecules through 
conjugation to dextran, high affinity is also achieved via avidity effects. We, and others, 
have described the synthesis of a variety of different OBOC libraries containing unnatural 
molecules (Alluri et al., 2003; Gao and Kodadek, 2013; Kritzer et al., 2005; Peng et al., 
2006; Suwal and Kodadek, 2013; Wu et al., 2014), all of which could be applied to this 
screening protocol, thus allowing many different chemotypes to be explored as antigen 
surrogates. Future work will focus on the isolation of many such molecules, optimization of 
the initial hits to higher affinity leads and the creation of chimeric molecules capable of 
delivering toxic cargo to B cells expressing the target receptor.
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Significance
The ability to manipulate antigen-specific immune responses would have a significant 
impact in several areas of biology and medicine. One such example is chronic lymphocytic 
leukemia, where the antigen-specific B cell receptor is an attractive drug target. Here we 
describe the first examples of high affinity and selectivity non-peptide ligands capable of 
engaging antigen-specific CLL B cells. The development of this technology opens the door 
to the development of chimeric “antigen-surrogate”-toxin conjugates capable of killing only 
pathogenic CLL cells without harming the normal function of the humoral immune system.
Materials and Methods
Experimental procedures
Design and synthesis of COPA library—The library was synthesized on 160 μm 
TentaGel MB NH2 resin (0.29 mmol/g loading, 520,000 beads/g, from Rapp Polymere, 
Germany). Total theoretical diversity of the library was 1.28 million and 2.5 g (2.5×520000 
beads) of resin was used to cover at least one copy of each library member. The TentaGel 
beads were derivatized with a peptoid linker as shown in Fig 1. A four-mer COPA library 
was synthesized following the linker using solid-phase sub-monomer methods and split-and-
pool techniques from (R) and (S) stereoisomers of 5-chloropentenoic acids and 
commercially available 20 different primary amines. The pentenoic acid sub-monomers (as 
depicted in Fig. 1) were synthesized following the protocols described in our previous paper 
(Aquino et al, Nature Chemistry 2011). To correlate differences in the mass of fragment ions 
with absolute stereochemistry the S-isomer was synthesized with an ethyl group at the C4 
position. The synthesis of COPA oligomers was described in details by Aquino et al (Nature 
Chemistry 2011). The synthesis of COPA oligomers was described in details by Aquino et 
al. (Aquino et al., 2011). To determine the quality of the library, 24 random beads were 
isolated from the library and treated individually with 20 µL of CNBr solution to release the 
compounds. The parent ion mass of the compounds was determined by MALDI-TOF and 
the sequence of the unknown COPA tetramer was determined by multiple sequence specific 
product ions obtained either from [M+2H]2+ or [M+3H]3+ or from both precursor ions by 
ESI Linear Ion Trap Mass Spectrometer (LTQ-ETD, ThermoFinnigan). The method of 
structure elucidation of COPA oligomers by MALDI and LTQ-ETD mass spectrometry was 
described in details by Sarkar et al. (Sarkar et al., J. Am. Soc. Mass Spectrom., 2013). From 
LTQ-ETD fragmentation patterns, the sequence of the COPA oligomers was decoded 
unequivocally for 22 out of 24 (91%) random beads. Representative spectra of MALDI-MS 
and ETD fragmentation patterns from a random hit bead are shown in Supp. Fig. S1.
Expression and purification of CLL BCR IgGs—CLL monoclonal antibodies (CLL 
014, CLL 068, CLL 169 and CLL 183) were expressed as IgG isotype from IgG-lambda or 
IgG-kappa (light chain) and IgG-gamma (heavy chain) expression plasmids obtained from 
professor Nicholas Chiorazzi Laboratory (Feinstein Research Institute, NY). The cloning, 
expression, and purification of mAbs were performed as reported by Seiler et al. (Seiler et 
al., 2009)._Heavy and light chain variable gene segments from CLL clones were amplified 
and sub-cloned into IgG heavy chain and IgG light chain expression plasmids to express the 
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CLL antibodies as IgG isotype. Human embryonic kidney 293 T (HEK 293T) cells were 
transiently co-transfected with heavy and light chain plasmids and grown for 5 days in 
serum free media supplemented with nutridoma-SP (from Roche Applied Science). CLL 
antibodies were purified from media on a Protein G Plus agarose column (from Thermo 
Scientific), eluted in 1×PBS and stored in 1% BSA at −20 °C before use.
In order to display full length IgG1 on cell surface, the heavy chain trans-membrane (TM) 
domain of human IgG1 was added to the C terminus of human CH3 domain in expression 
vector pIg-gamma. Primers used for TM cloning are shown in supporting information (Fig 
S4). The Surface membrane immunoglobulins (smIg) were expressed on transiently co-
transfected HEK 293 T cells and the expression level (CLL 014, CLL 068, CLL 169 and 
CLL 183) was determined by staining cells with Goat anti-human Fc-IgG conjugated to 
allophycocyanine (Fc-APC, from Jackson ImmunoResearch Laboratory Inc) and analyzing 
by fluorescence activated cell sorting (BD FACSCanto II ).
High-throughput bead-based screening of COPA library—The TentaGel beads 
displaying COPA library were pre-blocked with 1×TBST StartingBlock (Tris-buffered 
saline, pH 7.5, 0.05% Tween 20) containing 1% BSA before incubation with a 1:500 
dilution of goat F(ab')2-anti-human IgG Qdot 655 (Life Technologies) for 45 min at RT in 
1×TBST. The beads were visualized under a fluorescence microscope (Olympus BX-51) 
equipped with a 10×DAPI filter. Any beads emitting red light were collected manually by a 
micropipette and discarded. The process was repeated by incubating with 100 nM of pooled 
human IgG (from Sigma-Aldrich) following goat F(ab')2-anti-human IgG-Qdot. The 
denuded COPA library beads were incubated with 300 nM of CLL BCR antibodies (100 nM 
each of CLL 068, CLL 169 and CLL 183) in binding buffer for 45 min at RT followed by 
incubation with a 1:500 dilution of goat F(ab')2-anti-human IgG Qdot for 45 min at RT. 
Individual beads emitting red fluorescent light were collected manually using a 
micropipette. A total of 110 beads (brightly fluorescent) were collected, washed with 
1×TBST, treated with 1% SDS at 90 °C for 10 min to remove bound proteins, Qdot 
conjugated antibodies and any non-specific proteins bound to the beads. In the final rounds 
of selection process initial hit beads were incubated serially with CLL 068, CLL 169 and 
then CLL 183 to separate the individual hits. A total of 18 hit beads against CLL 169 mAb 
and 14 hit beads against CLL 183 were identified.
The hit beads were treated with 20 μL CNBr solution overnight to release the compounds 
and the sequence of the compounds were elucidated by MS and tandem MS/MS using 
4800Plus MALDI-TOF Analyzer (AB SCIEX) LTQ-Orbitrap XL (Thermo Scientific), San 
Jose, CA, USA) equipped with ETD at a resolving power of 60,000 at m/z 400. The 
structures of the hit compounds were elucidated by careful analysis of the product ions.
Biophysical characterization of initial hit compounds—Putative hit compounds (14 
for CLL 169 and 9 for CLL 183) were resynthesized with a fluorescein or biotin group at the 
linker position and purified on HPLC using C18 reverse phase column. For the fluorescence 
polarization experiment, fluorescein-COPA compounds (50 nM) were added to the serially 
diluted CLL BCR mAbs in binding buffer (50 mM Tris, 100 mM NaCl, 0.05% Tween 20, 
pH 7.6) in a 384-well microtiter plate and incubated in the dark at room temperature until 
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the binding reached to the equilibrium. Fluorescence polarization (mP units) was measured 
on an EnVision Multilabel Reader from Perkin Elmer. For ELISA, biotin-tagged compounds 
and peptide were immobilized on a streptavidin or neutravidin coated 96-well microtiter 
plate and titrated with serially diluted CLL mAbs for 45 min at RT, followed by a 1:5000 (1-
Step Ultra TMB ELISA substrate) or 1:20,000 (SuperSignal West Pico Chemiluminescent 
Substrate, Thermo Scientific) dilution of IgG1 conjugated HRP (Southern Biotech) for 30 
min at RT. The plates were treated with 1-Step Ultra TMB ELISA substrate (3,3′, 5,5′ - 
tetramentyl benzidine) or West Pico chemiluminescent substrate (Thermo Scientific) 
according to the supplier's protocols and the data were recorded on an EnVision Multilabel 
Reader at 450 nm or on a Tecan Microplate Redaer (Infinite 200Pro) using blue light. For 
competitive ELISA, KMS5 (or 169-8) peptide was immobilized on to a neutravidin coated 
96-well microtiter plate and incubated with 120 nM of CLL 169 mAb for equilibrium 
binding. The multiwell plate was then treated with serial dilution of KMS5 (self 
competition) or 169-8 peptide or control (random side chains) for 45 min at RT followed by 
anti-IgG1-HRP antibody (1:20,000) for 30 min at RT. SuperSignal West Pico 
Chemiluminescent substrate was used for colorimetric development and the luminescence 
was recorded on a Tecan Microplate Reader (Infinite 200Pro)
Serum stability test of COPA compounds—Standard solutions of COPA compounds 
(1.0 mM) were prepared in DMSO. KMS5 (4 μL) was added to a mixture of H2O (96 μL) 
and human serum (100 μL; Sigma Aldrich), and incubated at 37°C. A 20 μL of plasma was 
aliquoted from the incubation solution at 0, 24, 48, 72, 96, 120 and 144 h time points. A 1 
µL of 0.2 mM internal standard COPA compound was added to the mixture and immediately 
applied to C18-spin column (Thermo Scientific). The COPA compounds were purified 
following supplier's protocol and eluted with a 40 μL of an elution solution (80% 
acetonitrile, 20% H2O). Resulting solution was diluted with 0.1% formic acid and analyzed 
by LC-MS ((LC/MS 1100 Series equipped with SBC18 column from Agilent)) with a linear 
gradient of (5% acetonitrile, 0.05% formic acid/aqueous solution) to (80% acetonitrile, 
0.05% formic acid/aqueous solution).
Peptide synthesis—169-8 peptide (CGSSG-DNYAAALAQRAR, grey-linker) was 
synthesized following standard solid-phase peptide synthesis (SPPS) protocol using HOBt 
(Hydroxybenzotriazole), HBTU (2-(1H-Benzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium 
Hexafluorophosphate), DIPEA (diisopropylethyl amine) and Fmoc-amino acid in DMF. 
Biotin-maleimide (from Sigma) or Fluorescein-5-maleimide (from Pierce) was conjugated to 
the peptide by Michael reaction through the free thiol group on Cys. Peptides were purified 
on HPLC using C18 reverse phase column, lyophilized and stored at −20 °C before use. 
Control peptide (CGSSG-FLAQKLWSALEY) was custom prepared from Sigma and the 
biotin was conjugated to it by Michael reaction using biotin-maleimide (from Sigma).
Multivalent COPA and peptide ligand synthesis on dextran polymer—Amino-
dextran was synthesized as previously reported (Nakamura et al., 2010). The synthesis and 
chemical characterization of dextran conjugates were described in details in our previous 
paper (Morimoto et. al., Bioconjugate Chem. 2014). In short, dextran (500 mg, average 
molecular weight 35,000–45,000, from Leuconostoc mesenteroids, Sigma) was dissolved in 
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50 mL of anhydrous DMF and treated with 126 mg of N,N′-carbonyldiimidazole and 250 µL 
of ethylenediamine. Aminodextran was treated with biotin-NHS ester in DMSO at 4 °C for 
overnight to conjugate biotin. COPA or peptide ligands were conjugated to the biotinylated-
dextran polymer through N-(α-Maleimidoacetoxy) succinimide ester (AMAS, from Thermo 
scientific) in DMSO for two hours in the dark. The unreacted reactants were removed by 
filtering through Amicon Ultra 4 mL centrifugal filter unit (10,000 NMWL, from Millipore). 
The ligand-dextran conjugate in the filter unit was recovered in 1×PBS according to the 
manufacturer's protocol. The concentration of biotin in the solution was quantitatively 
determined using the Fluorescence Biotin Quantitation Kit (Thermo Scientific). The 
procedure to estimate the number of ligands conjugated to dextran polymer is described in 
details in Supplemental experimental procedures.
Cell binding assay by flow cytometry—HEK 293 T cells grown to 70 % confluency 1 
day after passage were transiently co-transfected with IgG light chain (pIg-lambda or-kappa) 
and heavy chain (pIg-gamma-TM) plasmids using 293-fectin transfection reagents (from 
Life Technologies) following the manufacturer's instructions. Cells were grown for 48 to 72 
h at 37 °C in 5% CO2, collected from the flask, aliquoted (∼ 0.5×106 cells) in each well of a 
microtiter 96-well plate and pre-blocked with 2% BSA in 1×PBS containing 0.1% sodium 
azide. The cells were incubated with biotin-tagged COPA compounds (50 nM) or 169-8 
peptide (20 nM) or dextran conjugated multivalent ligands for 30 min at 4 °C in binding 
buffer (1×PBS, pH 7.4 containing 1% BSA and 0.1% sodium azide) followed by treating 
with 1:40 dilution of Streptavidin-Phycoerythrin (saPE, from BD Bioscience) and Fc-APC 
for 30 min on ice. The cell surface expression of smIg (CLL 014, CLL 068, CLL 169 and 
CLL 183) was detected as APC signal and the binding was detected as PE signal in flow 
cytometry (BD FACSCanto II).
Binding assay of multivalent ligand-dextran conjugates with primary CLL 
Cells from patient—Cryopreserved PBMCs from CLL patient 169 (Jaglowski et al., 
2010) were thawed and recovered in AIM V media for 2 h at 37 °C in 5% CO2. Re-
suspended PBMCs in 1×PBS were carefully passed through a density gradient using Ficoll-
Paque Plus (from GE Healthcare) to remove the dead cells. B cells were further purified 
using a B cell purification kit (from Miltenyi Biotec) following the supplier's protocols. 
Four-color flow cytometry-based analysis was carried out using streptavidin conjugated PE 
(to determine binding affinity), anti-human CD5-APC antibody and anti-human CD19-FITC 
antibody (to identify CD5+/CD19+ CLL B cell populations, from BD biosciences), and Po-
Pro dye (for the staining of dead cells, from Life Technologies). About 0.4×106 cells were 
aliquoted into 96-well microtiter plate and incubated with 1×PBS containing 2% BSA and 
0.1% sodium azide for blocking followed by binding with biotin conjugated multivalent 
COPA, peptide ligand, control COPA compound and control peptide in binding buffer for 
30 min on ice. The cells were stained with streptavidin conjugated PE, anti-CD5-APC 
antibody, anti-CD19-FITC antibody, and Po-Pro dye for 30 min on ice and analyzed on BD 
FACSCantoII for recognition to multivalent antigen surrogates.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Design and solid-phase synthesis of a one bead one compound library of chiral 
oligomers of pentenoic acids (COPAs)
a. General synthetic scheme for the solid-phase synthesis of COPAs. b. General structure of 
the library used in this study comprised of a peptoid unit in the first position followed by 
three COPA units. The part of the structure shown in grey is an invariant linker present in all 
of the molecules. The library was constructed by split and pool synthesis on 160 μm 
TentaGel beads (0.29 mmol/g loading). C. Structures of the acid and amine sub-monomers 
employed in the library synthesis. By using 20 amines at each of the four variable positions 
and either (R)-2-methyl-5-chloro-3-pentenoic acid or (S)-2-methyl-4-ethyl-5-chloro-3-
pentenoic acid at positions 2-4, the total theoretical diversity of the COPA library was 1.28 
million compounds. 2. g of resin (≈ 1.3 million beads) was used to create the library.
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Figure 2. Schematic of the high-throughput bead-based screening strategy
The combinatorial library shown in Fig. 1 (≈ 1.2 million beads) was first incubated with 
goat anti-human IgG secondary antibody conjugated to a red quantum dot (QD) and beads 
that bound the secondary antibody, as judged by the presence of a red halo when observed 
under a low power fluorescence microscope, were removed using a pipette. The remainder 
of the beads were then incubated with a mixture of human IgGs obtained from individuals 
who did not have CLL, followed, after washing, by the quantum dot-conjugated secondary 
antibody. Again, fluorescent beads were removed from the population. The denuded library 
was then screened against a mixture of the CLL monoclonal Igs, CLL 068, 169 and 183 
(100 nM each), followed by the QD-conjugated secondary antibody. The fluorescent beads 
were pooled and stripped of protein. They were again exposed to control human IgGs and 
QD-conjugated secondary and beads with any noticeable fluorescence were removed. 
Finally, the remainder of the beads were exposed to the three CLL antibodies, one at a time, 
followed by QD-conjugated secondary antibody. The fluorescent beads were collected and 
placed in the wells of a microtiter plate (one bead per well). The compounds were released 
from the bead using CNBr and the structures were determined using a combination of 
MALDI and LTQ-ETD Mass spectrometry. See also Supp. Fig. S1.
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Figure 3. Binding properties of the library screening hits
a. Biotinylated derivatives of six of the COPA screening hits found to bind to CLL 169 in 
solution (Supp. Fig. S3) were immobilized on streptavidin-coated ELISA plates and titrated 
with the CLL 169 monoclonal Ig, followed, after washing, by mouse-anti human IgG1-HRP. 
The KD of the highest affinity complex (KMS5) was 90 ± 20 nM (b) Chemical structure of 
the biotinylated derivative of KMS5. (c) Selectivity of KMS5 for CLL 169. Immobilized 
KMS5 was titrated with the indicated antibodies, followed by the HRP-conjugated 
secondary antibody. Error bars indicate standard deviation (SD) of data obtained from three 
independent experiments. See also Supp. Fig. S3.
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Figure 4. Comparison of the COPA and peptide ligands for CLL 169
(a) Competition binding assays in which the CLL 169 Ig-containing solution (120 nM) was 
blocked with the indicated concentration of soluble KMS5, KMS5-dextran, 169-8 peptide, 
or a control peptide, then added to an ELISA plate displaying immobilized KMS5. After 
washing the level of bound antibody was determined using mouse anti-human IgG1 
antibody conjugated to HRP. (b) Biotinylated derivatives of COPA KMS5 or peptide 169-8 
(DNYAAALAQRAR) were immobilized on streptavidin-coated ELISA plates and titrated 
with CLL 169 followed, after washing, by mouse-anti human IgG1-HRP. Data analysis and 
curve fitting were performed with GraphPad Prism 5.0 (GraphPad Software) using a 
nonlinear regression method. Error bars indicate standard deviation (SD) of data obtained 
from three independent experiments.
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Figure 5. Flow cytometry-based analysis of ligand binding to cells displaying different CLL 
BCRs
(a) Schematic depiction of the assay. The pIg-gamma expression vectors were re-engineered 
by introducing a transmembrane (TM) domain at the C-terminus of the CH3 constant region 
to express CLL BCR as surface membrane immunoglobulin (smIg). HEK 293 T cells were 
transiently transfected with pIg gamma-TM and Ig lambda/kappa plasmid pairs for CLL 
014, CLL 068, CLL 169 and CLL 183 monoclonal Igs and the expression levels of these 
smIgs were determined by staining the cells with anti-human Ig Fc conjugated to 
allophycocyanin (anti-huIgFc-APC) flowed by analysis using flow cytometry. The plots 
indicate that all four of the smIgGs were expressed (bottom row, panel b). The cells were 
then mixed with a biotinylated dextran polymer displaying 20-30 copies of the COPA 
KMS5 or peptide 169-8. See also Supp. Fig. S5. (b) Flow cytometry plots obtained by 
treating the cells expressing the indicated smIg with the selecting antibody or dextran 
polymer, followed by PE-conjugated streptavidin (SA-PE). See also Supp. Fig. S7.
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Figure 6. Flow cytometry-based analysis of ligand binding to primary B cells from patients
Purified CLL 169 B cells from PBMCs were incubated with multivalent compound (KMS5-
dex-biot), peptide (169-8pept-dex-biot) or controls (COPA compound and peptide that were 
not selected as CLL 169 ligands) followed by staining and flow cytometry analysis. The 
stains used were phycoerythrin (PE)-conjugated streptavidin (SA-PE), anti-human CD5-
APC antibody, anti-human CD19-FITC antibody, and Po-Pro dye, which dyes dead cells. 
(a) Leukemic B cell populations (CD5+/CD19+/Po-Pro-) and regular B cell populations 
(CD5-/CD19+/Po-Pro-) from CLL 169 patient are shown in Q2 and Q3 quadrants, 
respectively, on the dot plot. (b) Observed level of SA-PE staining of CD5+/CD19+/Po-Pro- 
CLL 169 B cells after incubation with the dextran conjugates indicated. (c) Observed level 
of SA-PE staining of regular B cell populations (CD5-/CD19+/Po-Pro-) after incubation with 
the dextran conjugates indicated. (d) Observed level of SA-PE staining of CD5+/CD19+/Po-
Pro-CLL B cells obtained from a different patient (not CLL 169) after incubation with the 
dextran conjugates indicated (See also Supp. Fig. S7).
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